文献速递腹部MR

R2与R2* MRI评估未分化高铁蛋白血症诊断人群的肝铁含量及其对临床决策的影响

R2 and R2* MRI assessment of liver iron content in an undifferentiated diagnostic population with hyperferritinaemia, and impact on clinical decision making.
PubMed 文献 · Eur J Radiol · 2020-12-10

研究在32例血清铁蛋白升高(两次间隔4周均>500 μg/L)的未分化患者中,于1.5 T行3D六回波GRE mDIXON-Quant序列R2*定量并同步生成PDFF图,与Ferriscan® R2衍生的肝铁含量(LICR2)对比。R2*均值与LICR2高度线性相关(斜率±SE 43.35±1.88 s⁻¹ per mg/g;95%CI 39.5–47.2;P<0.001;R²=0.87)。向临床医生告知R2*结果后,14/32(44%)患者临床决策被修改,1例避免肝活检,1例经PDFF图诊断出未被识别的肝脂肪变。

要点

  • R2*与R2衍生肝铁含量高度线性相关(R²=0.87),可用于高铁蛋白血症患者的无创肝铁评估。
  • 告知R2*结果后44%(14/32)患者临床决策被修改,1例避免肝活检。
  • PDFF图可同期检出未被识别的肝脂肪变(1例)。

核心结论

  • 在真实世界高铁蛋白血症诊断人群中确认了R2与R2*的线性相关。
  • R2与R2* MRI无创评估肝铁含量是有用的临床工具,可改变这类患者的管理。

研究设计与样本

  • 前瞻性研究,纳入因血清铁蛋白升高转诊至医院血液科门诊的参与者32例(男27例、女5例)。
  • 纳入标准为两次血清铁蛋白水平间隔4周均>500 μg/L;排除MRI禁忌、针对高铁蛋白血症其他病因的临床相关检查尚未完成、终末期疾病。
  • 所有MRI于1.5 T完成;R2*定量采用3D六回波GRE序列(mDIXON-Quant,Philips),同步生成质子密度脂肪分数(PDFF)。
  • R2图像按许可方(Ferriscan®)规定在20分钟内采集并报告;记录临床医生基于R2*与R2衍生肝铁含量(LICR2)的解读和患者管理。

关键影像表现/征象

  • PDFF图诊断出1例未被识别的肝脂肪变。
  • 原文未报告其他影像征象。

诊断标准与关键数值

  • R2*均值与LICR2高度相关:斜率±SE 43.35±1.88 s⁻¹ per mg/g,95%CI 39.5–47.2,P<0.001,R²=0.87。
  • 采用Pearson相关、线性回归分析和ROC曲线,P<0.05为显著。

临床应用与阅片要点

  • 向临床医生告知R2*结果后,14/32(44%)高铁蛋白血症患者临床决策被修改(与仅依据血清铁蛋白相比)。
  • 基于LICR2和R2*,1例患者避免了肝活检。
  • R2*定量可同步获得PDFF图,有助于发现肝脂肪变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To confirm the linear correlation between Ferriscan® R2 (1/T2 Relaxomatry) and R2* (1/T2* Relaxometry) derived 3D Gradient echo (GRE) mDIXON-Quant sequence (Philips) with simultaneous production of a proton density fat fraction (PDFF) in undifferentiated patients with hyperferritinaemia, and to prospectively determine the clinical utility of this tool in these patients by recording the impact on clinical decision-making.

MATERIALS AND METHODS: Participants referred to a hospital haematology outpatient clinic for investigation and management of elevated serum ferritin (two serum ferritin levels > 500 μg/L 4 weeks apart) were included in the study.

EXCLUSION CRITERIA: contraindications to MRI; clinically relevant investigations for alternative causes of hyperferritinaemia pending; and terminal illness. Thirty-two participants were recruited: 27 men, 5 women. All MRIs performed at 1.5 T. For R2* quantification, 3D six echo GRE sequence (mDIXON-Quant) was acquired. R2 images were acquired over 20 min as dictated and reported by the licensee (Ferriscan®). Clinician interpretation and patient management based on R2* and liver iron content derived from R2 (LICR2) was recorded. Pearson's correlations, linear regression analyses, and ROC curves were calculated. P value <0.05 was considered significant.

RESULTS: A high degree of correlation between mean R2* and LICR2 was observed in this novel patient population (slope ± SE of 43.35 ± 1.88 s-1 permg/g; 95 % CI 39.5-47.2; P < 0.001; R2 = 0.87). Clinical decision making was amended in 14/32 (44 %) patients with hyperferritinaemia following the disclosure of R2* results to clinicians, compared with serum ferritin alone. Liver biopsy was avoided in one patient based on LICR2 and R2*. Unrecognised hepatic steatosis was diagnosed in one patient from the PDFF map.

CONCLUSION: We have confirmed the linear correlation between R2 and R2* in a real-world diagnostic population with hyperferritinaemia. Non-invasive assessment of liver iron content (LIC) by R2 and R2* MRI is a useful clinical tool and alters management in these patients.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Craft ML, Edwards M, Jain TP, et al. R2 and R2* MRI assessment of liver iron content in an undifferentiated diagnostic population with hyperferritinaemia, and impact on clinical decision making. Eur J Radiol. 2020. PMID: 33373894. doi:10.1016/j.ejrad.2020.109473

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。